Globeflex Capital’s Myriad Genetics MYGN Stock Holding History

Globeflex Capital’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10,545	Closed	-$201K	–	510
2022 Q3	$201K	Buy	+10,545	New	+$242K	0.03%	351
2019 Q1	–	Sell	-27,297	Closed	-$794K	–	452
2018 Q4	$794K	Buy	27,297 +6,067	+29%	+$218K	0.19%	182
2018 Q3	$977K	Hold	21,230	–	–	0.19%	182
2018 Q2	$793K	Buy	21,230 +5,600	+36%	+$189K	0.16%	218
2018 Q1	$462K	Buy	+15,630	New	+$529K	0.1%	298
2014 Q3	–	Sell	-28,700	Closed	-$1.12M	–	629
2014 Q2	$1.12M	Buy	+28,700	New	+$1.07M	0.12%	204
2014 Q1	–	Sell	-10	Closed	–	–	667
2013 Q4	$0	Sell	10 -173,163	-100%	-$4.38M	﹤0.01%	669
2013 Q3	$4.07M	Sell	173,173 -3,765	-2%	-$107K	0.52%	82
2013 Q2	$4.75M	Buy	+176,938	New	+$5.13M	0.65%	46

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Globeflex Capital's MYGN Position: Q4 2022 in Review

Globeflex Capital sold out of Myriad Genetics (MYGN) in Q4 2022, closing a stake of 10,545 shares — an estimated $201K sold.

Globeflex Capital first reported a position in MYGN in Q2 2013 and held it in 9 quarters. The position peaked at $4.75M in Q2 2013. 197 funds tracked by Wall St. Rank hold MYGN as of Q4 2022.

Globeflex Capital reported no remaining Myriad Genetics position as of Q4 2022 after selling out during the quarter.
Globeflex Capital sold 10,545 Myriad Genetics shares in Q4 2022, an estimated $201K.
Globeflex Capital first reported a position in Myriad Genetics in Q2 2013 and held it in 9 quarters.
Globeflex Capital's Myriad Genetics position peaked at $4.75M in Q2 2013.
197 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2022.

Based on Globeflex Capital's 13F filing for Q4 2022, filed 10 Feb 2023.